Back to Interventions
Substance / Medication

Tamsulosin hydrochloride

SNOMED 108560009UMLS C0771774

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Benign prostatic hyperplasia
Hyperplasia of prostate

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Prostate specific Ag

LOINC 10508-0

secondary

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.
Shin Yu Seob, Zhang Li Tao, You Jae Hyung et al. · Clin Interv Aging · 2016
PMID: 27698559RCTFull text (PMC)
Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers.
Chu Nannan, Xu Hongrong, Wang Guoqin et al. · Clin Ther · 2015
PMID: 25465944RCT
Efficacy of tamsulosin hydrochloride in relieving "double-J ureteral stent-related morbidity": a randomized placebo controlled clinical study.
Singh Iqbal, Tripathy Sambit, Agrawal Vivek · Int Urol Nephrol · 2014
PMID: 25201459RCT
Smart spectrophotometric assessment of tamsulosin hydrochloride and tadalafil in their new pharmaceutical formulation for treatment of benign prostatic hyperplasia and erectile dysfunction.
Rezk Mamdouh R, Tantawy Mahmoud A, Wadie Mina et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2020
PMID: 31734571Observational
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia.
Dogan Mustafa, Kutluksaman Bunyamin, Keles Ibrahim et al. · Curr Eye Res · 2017
PMID: 28937828Observational
Clinical significance of prostatic-urethral angulation on the treatment outcome of patients with symptomatic benign prostatic hyperplasia treated with tamsulosin hydrochloride.
El-Tatawy Hassan, Gameel Tarek, El-enen Mohammed Abo et al. · Arch Ital Urol Androl · 2015
PMID: 26428648Observational
The Effect of Systemic Tamsulosin Hydrochloride on Choroidal Thickness Measured by Enhanced Depth Imaging Spectral Domain Optical Coherence Tomography.
Sari Erhan, Sari Esin Sogutlu, Yazici Alper et al. · Curr Eye Res · 2015
PMID: 25495762Observational
Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride.
Kawachi Yoshio, Sakurai Toru, Sugimura Sosuke et al. · Scand J Urol Nephrol · 2010
PMID: 20095868Observational
Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.
Tsuda Yasuhiro, Tatami Shinji, Yamamura Norio et al. · Br J Clin Pharmacol · 2010
PMID: 20642551ObservationalFull text (PMC)
Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Miyakita Hideshi, Yokoyama Eiji, Onodera Yasutada et al. · Int J Urol · 2010
PMID: 20735791Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X
Urology Physician

Urology

NUCC 208800000X
Find a Provider

Health Goals

Goals connected through associated conditions

Support Prostate Health

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tamsulosin hydrochloride (substance)
SNOMED CT
108560009
UMLS CUI
C0771774

Clinical Data

This intervention maps to 6 entities in the Healos knowledge graph.

2
Conditions
1
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.